Literature DB >> 20828350

Diagnosis and treatment of subclavian artery occlusive disease.

Patrick A Stone1, Mohit Srivastiva, John E Campbell, Albeir Y Mousa.   

Abstract

Atherosclerosis of the brachiocephalic vessels is uncommon in comparison to the prevalence of disease in the extracranial carotid arteries. Prior to 1980, occlusive disease of this vascular bed had been treated primarily with surgical intervention, which carried a significant rate of morbidity and mortality. In the last 30 years, however, minimally invasive endovascular techniques have become an important tool in the management of symptomatic patients. Angioplasty and stenting have been reported as a viable therapeutic option, producing good technical success and durability. Here, we examine the natural history of subclavian artery occlusive disease, along with the diagnostic evaluation and various treatment modalities currently available, with special attention paid to the evolution of the role of endovascular management.

Entities:  

Mesh:

Year:  2010        PMID: 20828350     DOI: 10.1586/erc.10.111

Source DB:  PubMed          Journal:  Expert Rev Cardiovasc Ther        ISSN: 1477-9072


  3 in total

1.  Treatment of subclavian artery stenosis: A case series.

Authors:  Reem Salman; Jane Hornsby; Lucie J Wright; Tarek Elsaid; Grace Timmons; Ahmed Mudawi; Vish Bhattacharya
Journal:  Int J Surg Case Rep       Date:  2015-12-17

2.  The Use of Transthoracic Echocardiography in Diagnosing Brachiocephalic-Subclavian Artery Stenosis.

Authors:  David Anwar; Renée P Bullock-Palmer
Journal:  CASE (Phila)       Date:  2018-02-15

3.  Combined Transradial and Transfemoral Approach With Ostial Vertebral Balloon Protection for the Treatment of Patients With Subclavian Steal Syndrome.

Authors:  Rami Fakih; Sudeepta Dandapat; Alan Mendez-Ruiz; Aldo A Mendez; Mudassir Farooqui; Cynthia Zevallos; Darko Quispe Orozco; David Hasan; James Rossen; Edgar A Samaniego; Colin Derdeyn; Santiago Ortega-Gutierrez
Journal:  Front Neurol       Date:  2020-10-22       Impact factor: 4.003

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.